

AVENTIS  
Form 425  
March 10, 2004

Filed by Sanofi-Synthélabo  
Pursuant to Rule 165 and Rule 425(a) under the United States Securities Act of 1933,  
as amended, and deemed filed pursuant to Rule 14d-2(b)(2) of the  
United States Securities Exchange Act of 1934, as amended

Subject Company: Aventis  
Commission File No. 001-10378  
Date: March 10, 2004

On March 10, 2004, Sanofi-Synthelabo issued the following press release.

In connection with the proposed acquisition of Aventis, Sanofi-Synthélabo has filed with the United States Securities and Exchange Commission (SEC), a registration statement on Form F-4 (File no: 333-112314), which includes a preliminary prospectus and related exchange offer materials, to register the Sanofi-Synthélabo ordinary shares (including Sanofi-Synthélabo ordinary shares represented by Sanofi-Synthélabo ADSs) to be issued in exchange for Aventis ordinary shares held by holders located in the United States and for Aventis ADSs held by holders wherever located. At the appropriate time, Sanofi-Synthélabo will file a Statement on Schedule TO with the SEC. **Investors and holders of Aventis securities are strongly advised to read the registration statement and the preliminary prospectus, the related exchange offer materials and the final prospectus and the Statement on Schedule TO (when available), and any other relevant documents filed with the SEC, as well as any amendments and supplements to those documents, because they will contain important information.** Investors and holders of Aventis securities may obtain free copies of the registration statement, the preliminary prospectus and related exchange offer materials, and the final prospectus and Statement on Schedule TO (when available), as well as other relevant documents filed with the SEC, at the SEC's web site at [www.sec.gov](http://www.sec.gov) and will receive information at the appropriate time on how to obtain transaction-related documents for free from Sanofi-Synthélabo or its duly designated agent.

\* \* \* \*

---

**Investor Relations**

Paris, March 10th, 2004

Jean-François Dehecq, Chairman and Chief Executive Officer of Sanofi-Synthelabo will present the Group comments on Aventis<sup>1</sup> Note d'information en réponse (official response) to the share and cash offer on Aventis shares at a meeting for financial analysts, institutional investors and journalists :

Thursday March 11th, 2004 at 14h30 Paris time (GMT+1)  
(1:30 p.m. London time GMT)

**HOTEL D'EVREUX**  
**19 Place Vendôme 75001 PARIS**

The meeting will be conducted in French with simultaneous English translation

The presentation will be accessible on our website : [www.sanofi-synthelabo.com](http://www.sanofi-synthelabo.com)

It will be possible to participate in the conference by dialing the following numbers 10 minutes before the conference starts:

France :	0 800 945 127/0 800 945 126	code : ocean
United Kingdom :	0 800 917 08 64/0 800 358 23 39	code : ocean
USA :	1 800 257 70 63	code : ocean
Germany :	0 800 101 19 65	code : ocean

1) Registered with AMF on March 4th, 2004 under number 04-135

***Investor Relations Department***

<i>Philippe Goupit</i>	<i>Director of Investor Relations</i>
<i>Arnaud Delépine</i>	<i>Investor Relations Europe</i>
<i>Sanjay Gupta</i>	<i>Investor Relations US</i>

***Contacts :***

*E-mail :* [investor-relations@sanofi-synthelabo.com](mailto:investor-relations@sanofi-synthelabo.com)

*Europe* *US*

*Tel : + 33 1 53 77 45 45* *Tel. : 1 212 551 42 93*

*Fax : + 33 1 53 77 42 96* *Fax : 1 212 551 49 92*

**Important Information:** In connection with the proposed acquisition of Aventis, Sanofi-Synthelabo has filed a registration statement on Form F-4 (File no. 333-112314) and will file additional documents with the United States Securities and Exchange Commission (SEC). **Investors are urged to read the registration statement and any other relevant documents filed with the SEC, including all amendments, because they contain important information.** Free copies of the registration statement, as well as other relevant documents filed with the SEC, may be obtained at the SEC's web site at [www.sec.gov](http://www.sec.gov). At the appropriate time, transaction-related documents may be obtained for free from Sanofi-Synthelabo.

In accordance with article 7 of COB regulation n° 2002.04, this press release was transmitted to Autorité des Marchés Financiers before its release.

